Showing 791-800 of 813 results for "".
- Pfizer’s JAK Inhibitor Improves Moderate-to-Severe AD Symptomshttps://practicaldermatology.com/news/pfizers-jak-inhibitor-improves-mild-to-moderate-ad-symptoms/2460413/Results from the second pivotal trial for abrocitinib reinforce the potential symptom relief that this Janus kinase 1 (JAK1) inhibitor offers patients living with moderate to severe atopic dermatitis (AD). Abrocitinib is an investigational oral once-daily JAK1 inhibitor being studied in patients a…
- RealSelf Survey: 36 Percent of US Adults Are Considering Cosmetic Treatmentshttps://practicaldermatology.com/news/realself-36-percent-of-us-adults-are-considering-cosmetic-treatments/2459933/More than four in five U.S. adults want to improve their personal well-being or appearance in 2019, and 36 percent are considering cosmetic treatments, according to new RealSelf survey. Fully 82 percent of U.S. adults plan to make changes related to their personal well-being and/or appearance in 2…
- Neova Launches New Line of Professional Grade Peelshttps://practicaldermatology.com/news/neova-launches-new-line-of-professional-grade-peels/2457604/Neova SmartSkinCare has introduced a new range of Professional Treatments developed exclusively for dermatologist use. The line of five new exfoliating peels integrate the newest and most advanced formulas with proven, established ingredients to produce visible results with minimal irritation and d…
- FDA Approves Cimzia for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-cimzia-for-moderate-to-severe-plaque-psoriasis/2457747/The FDA has approved extending the label for UCB's Cimzia (certolizumab pegol) to include a new indication in adults with moderate to severe plaque psoriasis. Cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or ph…
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is an autologous gene-co…
- Smart Beauty Devices Take Center Stage at CES 2018https://practicaldermatology.com/news/smart-beauty-devices-take-center-stage-at-ces-2018/2457927/The Computer Electronics Show is known as the see-and-be scene for techies – and beauty products and devices always take center stage. “Shopping for skincare products can be an overwhelming and confusing experience for our consumer because she is uncertain about what her skin really needs,” says S…
- NRS Introduces New Standard Classification and Pathophysiology of Rosaceahttps://practicaldermatology.com/news/nrs-introduces-new-standard-classification-and-pathophysiology-of-rosacea/2457979/The National Rosacea Society (NRS) is introducing a new standard classification and pathophysiology of rosacea. The updated system appears in the Journal of the American Academy of Dermatology. Developed by a consensus committee and review panel of 28 rosacea experts worldwide, the updated system…
- Gut Microbiome May Affect How Metastatic Melanoma Responds to Immunotherapyhttps://practicaldermatology.com/news/gut-microbiome-may-affect-how-metastatic-melanoma-responds-to-immunotherapy/2457986/The gut microbiome can influence how metastatic melanoma responds to immunotherapy, researchers from The University of Texas MD Anderson Cancer Center report in the journal Science. Patients with metastatic melanoma treated with anti-PD1 checkpoint blockade have their disease controlled longer if …
- Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in EBhttps://practicaldermatology.com/news/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-eb/2458075/The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to the Abeona Therapeutics Inc.’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. EB-101 is an autologous, ex-vivo gene-corrected cell therapy in which the COL7A1 gene is…
- Safe Hair Care Can Prevent Trichorrhexis Nodosahttps://practicaldermatology.com/news/safe-hair-care-can-prevent-trichorrhexis-nodosa/2458358/Trichorrhexis nodosa (TN) can be remedied through appropriate use of cleansing products, hair care and styling practices, new research suggests. The findings are published ahead of print in the Journal of Dermatological Treatment. TN Risk Factors Defined Researchers from Johns Hopkins School of …